• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy
Stroke causes long-term serious disability with global prevalence of 101 million people in 2019.1 Antithrombotic therapy is recommended for stroke secondary prevention depending on the acute ischemic stroke (AIS) subtype.2 One of the major causes of non-cardioembolic AIS is intracranial atherosclerosis, which requires single antiplatelet therapy (SAPT), mostly with aspirin.3,4 Dual antiplatelet therapy (DAPT) may reduce the risk of non-cardioembolic stroke by 29% in AIS attributable to severe intracranial stenosis when used for a limited period of time.
Source: Journal of Stroke and Cerebrovascular Diseases - November 16, 2022 Category: Neurology Authors: Gabriela Rusin, Jadwiga Kubica, Krzysztof Piotr Malinowski, Agnieszka S łowik, Anetta Undas Source Type: research

Safety and efficacy of periprocedural antithrombotics in patients with successful reperfusion after endovascular stroke treatment
We aimed to evaluate whether the overall harmful effect of periprocedural treatment with aspirin or heparin during endovascular stroke treatment is different in patients with a successful reperfusion after the procedure.
Source: Journal of Stroke and Cerebrovascular Diseases - August 24, 2022 Category: Neurology Authors: Wouter van der Steen, P. Matthijs van der Sluijs, Rob A. van de Graaf, Ruisheng Su, Lennard Wolff, Henk van Voorst, Heleen M. den Hertog, Pieter Jan van Doormaal, Adriaan C.G.M. van Es, Julie Staals, Wim van Zwam, Hester F. Lingsma, Ren é van den Berg, C Source Type: research

Aspirin platelet reactivity on platelet function and clinical outcome in minor stroke or transient ischemic attack
Whether aspirin platelet reactivity affects platelet function and clinical outcomes with different antiplatelet therapies in patients with mild stroke or transient ischemic attack (TIA) remains unclear. We conducted a subgroup analysis of the PRINCE trial.
Source: Journal of Stroke and Cerebrovascular Diseases - July 29, 2022 Category: Neurology Authors: Yanjie Xu, Weiqi Chen, Lingling Jiang, Yicong Wang, Xingquan Zhao, Liping Liu, Dongxiao Yao, Lei Guo, Yongjun Wang, Yuesong Pan, Yilong Wang Source Type: research

P2Y12 reaction units and ischemic and bleeding events after neuro-endovascular treatment
To investigate the associations of perioperative P2Y12 reaction units (PRU) measured using VerifyNow with ischemic and bleeding events, and to determine the PRU threshold in the setting of elective neuro-endovascular treatment (EVT) for intracranial/extracranial vascular disease in patients taking aspirin and clopidogrel.
Source: Journal of Stroke and Cerebrovascular Diseases - July 15, 2022 Category: Neurology Authors: Kyohei Fujita, Shoko Fujii, Sakyo Hirai, Hiroto Yamaoka, Mariko Ishikawa, Jun Karakama, Kazunori Miki, Masataka Yoshimura, Shigeru Nemoto, Kazutaka Sumita Source Type: research

Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window
We tested the hypothesis that blocking pro-inflammatory platelet-activating factor receptor (PAFR) with LAU-0901 (LAU) plus administering a selected docosanoid, aspirin-triggered neuroprotectin D1 (AT-NPD1), which activates cell-survival pathways after middle cerebral artery occlusion (MCAo), would lead to neurological recovery. Dose-response and therapeutic window were investigated.
Source: Journal of Stroke and Cerebrovascular Diseases - June 17, 2022 Category: Neurology Authors: Madigan M. Reid, Andre Obenaus, Pranab K. Mukherjee, Larissa Khoutorova, Cassia R. Roque, Nicos A. Petasis, Reinaldo B. Oria, Ludmila Belayev, Nicolas G. Bazan Source Type: research

Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial
The effect of interventions on functional impairment is an important outcome in stroke prevention trials and should be considered as an adjunct to counting discrete events. In the NAVIGATE-ESUS trial, 7213 patients with recent embolic strokes of undetermined source were randomized to rivaroxaban (15 mg once daily) or aspirin (100 mg daily). After 11 months there was no effect on the prevention of recurrent stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - March 12, 2022 Category: Neurology Authors: Jackie Bosch, Lesly A. Pearce, Mukul Sharma, Michelle Canavan, William N. Whiteley, Robert Mikul ík, Hardi Mundl, Salim Yusuf, Robert G. Hart, Martin J. O'Donnell Source Type: research

Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting
Treating high-risk transient ischemic attack (TIA) with dual antiplatelet therapy (DAPT) reduces subsequent ischemic stroke risk yet current rates of clopidogrel-aspirin treatment are uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - October 11, 2021 Category: Neurology Authors: Andrea R. Lendaris, Samantha Lessen, Natalie T. Cheng, Benjamin W. Friedman, Charles Esenwa, Daniel L. Labovitz, Shyam Prabhakaran, Richard B. Lipton, Ava L. Liberman Source Type: research

Risk Factors Control and Early Recurrent Cerebral Infarction in Patients with Symptomatic Intracranial Atherosclerotic Disease
Stroke caused by intracranial atherosclerotic disease (IAD) has the highest risk of early recurrence when compared to other stroke subtypes.1 Despite intensive medical management, the 1-year recurrence risk is as high as 15%.2,3 Uncontrolled risk factors may substantially influence stroke recurrence in symptomatic IAD. In the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial, uncontrolled systolic blood pressure (SBP) (>140 mmHg) and elevated cholesterol (>200 mg/dL) were associated with increased recurrent stroke during follow-up.
Source: Journal of Stroke and Cerebrovascular Diseases - June 30, 2021 Category: Neurology Authors: Victor J. Del Brutto, David S. Liebeskind, Jose G. Romano, Iszet Campo-Bustillo, George Cotsonis, Azhar Nizam, Shyam Prabhakaran, MYRIAD investigators Source Type: research

Atrial Cardiopathy Biomarkers and MRI-Based Infarct Patterns in Patients with Embolic Strokes of Undetermined Source
Embolic stroke of undetermined source (ESUS) refers to non-lacunar ischemic strokes without a well-recognized cardioembolic source or stenosis of a large vessel supplying the infarcted terroritory1 and accounts for 9-25% of all ischemic stroke cases.2 Although ESUS can be related to various potential sources of thromboembolism, the most prevalent embolic source seems to be the heart. Thus, ESUS may be more responsive to anticoagulant therapy than antiplatelet therapy.1 However, recent clinical trials have failed to confirm that oral anticoagulation lowers the risk of stroke recurrence, relative to aspirin.
Source: Journal of Stroke and Cerebrovascular Diseases - June 19, 2021 Category: Neurology Authors: Yoon-Kyung Lee, Byung-Cheol Gwak, Byeol-A Yoon, Dae-Hyun Kim, Jae-Kwan Cha Source Type: research

Aspirin Use and Risk of Subdural Hematoma: Updated Meta-Analysis of Randomized Trials
Subdural hematomas are an uncommon, but a serious, bleeding complication of antithrombotic therapies. We update our previous inconclusive meta-analysis to better estimate the risk of subdural hematoma associated with aspirin use.
Source: Journal of Stroke and Cerebrovascular Diseases - June 13, 2021 Category: Neurology Authors: Robert G. Hart, Lesly A. Pearce, Philip B. Gorelick, Ben J. Connolly, Luciana Catanese Source Type: research

Big Data Analysis of the Risk of Intracranial Hemorrhage in Korean Populations Taking Low-Dose Aspirin
In this study, the risk of intracranial hemorrhage in patients taking low-dose aspirin was assessed.
Source: Journal of Stroke and Cerebrovascular Diseases - June 11, 2021 Category: Neurology Authors: Tae Gon Kim, Soyoung Yu Source Type: research

COVID-19 Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin
A 31-year-old sexually active, non-smoker female with a past medical history of spina-bifida and idiopathic thoracolumbar scoliosis status post hardware spinal fusion surgery five years ago presented with a one-day history of severe holocranial headaches associated with nausea and visual changes. A thorough neurological examination was intact. She complained of mild cough as well. She had a positive nasopharyngeal swab for SARS-CoV-2 on RT-PCR assay. A comprehensive drug screen including amphetamines, cocaine, nicotine, alcohol, and ecstasy as well as a pregnancy test were negative; coagulation profile was within normal limits.
Source: Journal of Stroke and Cerebrovascular Diseases - April 12, 2021 Category: Neurology Authors: Tarab Mansoor, Ali A. Alsarah, Hossein Mousavi, Javed Elyias, Tarun Girotra, Omar Hussein Tags: Case Report Source Type: research

Safety of Ticagrelor in Moderate and Severe Acute Ischemic Stroke: A Single-Center Retrospective Review
Ticagrelor is a potent P2Y12 receptor antagonist that may have a role in acute ischemic stroke (AIS), particularly in patients with symptomatic atherosclerotic disease.1,2 Recently, a large randomized control trial demonstrated a significant reduction in stroke or death within 30 days following minor stroke or TIA with ticagrelor plus aspirin versus aspirin alone.3 Studies of ticagrelor have focused on patients with minor stroke or TIA; however, safety of ticagrelor following more severe ischemic strokes is unknown.
Source: Journal of Stroke and Cerebrovascular Diseases - April 3, 2021 Category: Neurology Authors: Stephen W. English, David R. Landzberg, Nirav R. Bhatt, Michael R. Frankel, Digvijaya Navalkele Source Type: research

Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy
About 15% of patients with non-valvular atrial fibrillation might require percutaneous coronary interventions (PCIs) with stent placement to treat obstructive coronary artery disease. Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (aspirin) and P2Y12 antagonist is recommended after PCI. Patients requiring DAPT also require treatment with oral anticoagulation for atrial fibrillation. We conducted a meta-analysis to identify the antithrombotic regimen associated with the lowest rate of bleeding and thromboembolic events in non-valvular atrial fibrillation after PCI.
Source: Journal of Stroke and Cerebrovascular Diseases - February 9, 2021 Category: Neurology Authors: Aaron Desai, Cesar Escamilla-Ocanas, Deepika Dilip, Hamidreza Saber, Rahul Damani Source Type: research

Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis
Cilostazol has promise as an alternative to aspirin for secondary stroke prevention given its vasodilatory and anti-inflammatory properties in addition to platelet aggregation inhibition. We aimed to conduct a systematic review and meta-analysis to estimate the efficacy and safety of cilostazol compared to aspirin for stroke prevention in patients with previous stroke or transient ischemic attack (TIA).
Source: Journal of Stroke and Cerebrovascular Diseases - December 31, 2020 Category: Neurology Authors: Michelle P. Lin, James F. Meschia, Neethu Gopal, Kevin M. Barrett, Owen A. Ross, Nil üfer Ertekin-Taner, Thomas G. Brott Source Type: research

Pages: 1  2  3  4  5